Thank you, Melinta Therapeutics, for supporting AWE's mission to create more diversity in corporate America. Together we can increase the number of women in corporate leadership and on boards to improve the global economy.
Melinta Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to introducing new antibiotics that meet the ever-present challenge posed by dangerous and increasingly resistant bacteria. They are completing Phase 3 development of their late-stage investigational antibiotic, Baxdela (delafloxacin), for serious hospital-treated skin infections known as acute bacterial skin and skin structure infections (ABSSSI). Melinta is also developing, through the application of Nobel Prize-winning science and a proprietary drug discovery platform, novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens, which cause the majority of life-threatening hospital infections.